2 FTSE 100 growth giants that could fund your retirement

These two rising FTSE 100 (INDEXFTSE:UKX) stocks could help you to a comfortable old age.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re investing for your retirement, what should you do differently? I’d say nothing at all, because a good retirement investment strategy is simply a good investment strategy.Strategies aimed at maximising your long-term returns have a habit of turning out to be the most successful, whatever your age or plans.

To that end, there are many good stocks that should be good for long-term growth, and today I’m looking at two from the FTSE 100.

A new growth phase

AstraZeneca (LSE: AZN) has suffered a bit in recent years as the loss of patent protection on some key drugs has opened the way for cheap generic competition. Earnings have fallen as a result and the company has been working hard to focus on its core business and reinvigorate its development pipeline. 

You might imagine that the shares have had a few tough years as we await news of a return to earnings growth. But you’d be wrong, as AstraZeneca shares have actually gained 65% over the past five years, to 4,725p today. And over that period, the company has kept on paying dividends of around 5% and better.

So how will AstraZeneca do in a renewed period of sustainable growth? I think it will do very well indeed, and that were are on the verge of exactly that. Analysts seem to think the turnaround in earnings per share should happen in 2018 as the changes made by Pascal Soriot since he took the helm in 2012 are bearing fruit.

As of 2016 results time, 12 new drugs candidates had reached the Phase III stage or were under regulatory review, targeting oncology, cardiovascular and metabolic diseases and respiratory conditions, which are all growing first-world problems. And there are some clear candidates to become the blockbusters of tomorrow.

AstraZeneca shares are on a P/E of 15 on 2018 forecasts, and I reckon that could shrink rapidly over the next 10 years and make the shares look a real bargain today.

A hidden secret

GKN (LSE: GKN) is a company that has largely evaded me so far as its share price has somewhat stagnated in recent years, but while searching for solid growth candidates it has caught my eye. There was a minor dip in 2015, but since the end of 2012 the automotive engineer has grown its earnings per share by 18% — and forecasts suggest a gain of 37% by 2018.

Over the same period, dividends have been modest in the 2%-3% range, but they’re progressive and have been growing well ahead of inflation. That trend is expected to continue, and for me a dividend that is growing reliably in real terms is a very desirable thing.

Results for 2016 showed a 22% rise in revenue, which boosted adjusted pre-tax profit by 12%, and forecasts suggest two more years of earnings growth. And despite a one-off restructuring charge of £39m, the firm reckoned that has resulted in annualised savings of £30m.

We’re looking at a company here that has come through a restructuring phase, has what I see as attractive growth potential over the next decade and more, and whose shares are trading on a forward P/E of only around 10. That looks to me to be a great candidate for a retirement portfolio.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of GKN. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 ridiculously cheap shares to consider buying now

Harvey Jones can see plenty of cheap shares on the FTSE 100 and says the Iran conflict isn't the main…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

£1,000 buys 1,712 shares in this red hot defence-related penny stock that’s tipped to soar 75%

Edward Sheldon has just spotted a penny stock that appears to offer the winning combination of growth, value, and share…

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

£7,500 invested in Aston Martin shares 5 weeks ago is now worth…

With Aston Martin shares down 66% in 13 months and now trading for just 40p each, should I buy the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

With a P/E ratio of 11, could buying this stock be like investing in Meta Platforms in 2022?

I think Adobe shares today look a lot like Meta stock in October 2022. Could this be another chance for…

Read more »

Investing Articles

Should I wait for the point of maximum panic to buy UK shares?

Harvey Jones is keen to buy cheap UK shares for his Self-Invested Personal Pension. But should he jump in now…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Dividend Shares

The dividend yield of these 2 income stocks just jumped almost 25%

Jon Smith points out an income stock he feels is attractive given the recent share price slump, but also outlines…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Investing Articles

As Rolls-Royce buys its own shares, should I buy more too?

Buying Rolls-Royce shares has been one of James Beard’s best decisions. But is it possible to have too much of…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing For Beginners

Down 43% in a month, what on earth’s going on with the Vistry share price?

Jon Smith points out why the Vistry share price is enduring a tough period, and provides his outlook for the…

Read more »